Definium Therapeutics (DFTX) said Wednesday its phase 3 Voyage study of DT120 lysergide orally disintegrating tablets in adults with generalized anxiety disorder met its primary endpoint.

The treatment produced an 11.6-point LS mean reduction in HAM-A score at Week 12, compared with 6.2 points for placebo, for a placebo-adjusted difference of 5.4 points (p<0.0001), it said.

Definium said efficacy was observed as early as Day 2 and sustained through Week 12. DT120 was generally well tolerated, with no new safety signals reported, it added.